Barron's September 08, 2026 • 14:12

Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's

By George Glover

Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's

Amgen stock drops after Novartis’ disappointing trial results.

Amgen stock was sliding Tuesdayand its all Novartis fault.
Copyright ©2026Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read Full Article on Original Site ↗ ← Back to News List

More from Barron's

Former KLM CEO allegedly sparks fire onboard after ignoring power bank rule - New York Post

September 19, 2026

Iconic Carnegie Deli reopens after 10-year absence — with noticeable differences in service, soup, pastrami - New York Post

September 19, 2026

Beloved restaurant chain dwindles from 850 locations to 87, but expert sees 'a lot of life left' - foxnews.com

September 19, 2026

Bitcoin is back at $80,000 as rest of crypto joins the rally: Chart of the Day - Yahoo Finance

September 19, 2026